Nat Commun:复旦大学实现高效脑靶向药物递送

2019-08-10 黄辛 科学网

复旦大学基础医学院占昌友研团队设计了一种新颖的脑靶向脂质体药物,血液循环过程中可精准“钓”取内源性载脂蛋白并维持其生物活性,实现高效的脑靶向药物递送。8月8日,相关研究成果在线发表于《自然-通讯》。

复旦大学基础医学院占昌友研团队设计了一种新颖的脑靶向脂质体药物,血液循环过程中可精准“钓”取内源性载脂蛋白并维持其生物活性,实现高效的脑靶向药物递送。8月8日,相关研究成果在线发表于《自然-通讯》。
 
脂质体是当前临床应用最为广泛的一类纳米药物载体。靶向脂质体药物的相关研究在近40年时间内十分活跃,但至今仍未实现临床转化,急需从源头设计调整思路。
 
血浆中存在多种载脂蛋白可跨越血脑屏障,而脑内Aβ蛋白的清除机制之一,是通过结合多种载脂蛋白的脂质结合区域,同时暴露受体结合区域,经血脑屏障上对应的受体介导转运至外周。因相关受体可双向转运,也能将外周配体转运至脑内。研究人员仿生Aβ蛋白设计获得无毒短肽,修饰在脂质体表面后,在血液循环过程中主动吸附目标载脂蛋白的脂质结合区域,同时将受体结合区域暴露在脂质体表面,发挥高效脑靶向性作用。
 
据悉,该目标短肽修饰的脂质体载抗肿瘤药阿霉素后,成功治疗多种原位脑肿瘤(脑胶质瘤和髓母细胞瘤),均显著延长模型鼠的中位生存期。
 
专家表示,该脑靶向递药策略突破传统设计思路,主动利用血浆中功能性蛋白,克服传统脑靶向脂质体药物的多种缺陷,且安全性高,具有较好的临床转化前景,相关研究成果已申请PCT国际专利。同时,该递送策略在人血中具有类似的功能,或可应用于脂质体以外的药物递送系统上。

原始出处:

Zui Zhang, Juan Guan, Zhuxuan Jiang, et.al. Brain-targeted drug delivery by manipulating protein corona functions. Nature Communications 08 August 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087571, encodeId=7316208e57185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 22 14:21:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883827, encodeId=874e188382eeb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 18 08:21:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810509, encodeId=942a181050987, content=<a href='/topic/show?id=6ae8851806f' target=_blank style='color:#2F92EE;'>#脑靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85180, encryptionId=6ae8851806f, topicName=脑靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Dec 25 14:21:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538569, encodeId=c918153856967, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Aug 12 07:21:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2020-05-22 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087571, encodeId=7316208e57185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 22 14:21:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883827, encodeId=874e188382eeb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 18 08:21:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810509, encodeId=942a181050987, content=<a href='/topic/show?id=6ae8851806f' target=_blank style='color:#2F92EE;'>#脑靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85180, encryptionId=6ae8851806f, topicName=脑靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Dec 25 14:21:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538569, encodeId=c918153856967, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Aug 12 07:21:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-10-18 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087571, encodeId=7316208e57185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 22 14:21:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883827, encodeId=874e188382eeb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 18 08:21:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810509, encodeId=942a181050987, content=<a href='/topic/show?id=6ae8851806f' target=_blank style='color:#2F92EE;'>#脑靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85180, encryptionId=6ae8851806f, topicName=脑靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Dec 25 14:21:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538569, encodeId=c918153856967, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Aug 12 07:21:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087571, encodeId=7316208e57185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 22 14:21:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883827, encodeId=874e188382eeb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 18 08:21:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810509, encodeId=942a181050987, content=<a href='/topic/show?id=6ae8851806f' target=_blank style='color:#2F92EE;'>#脑靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85180, encryptionId=6ae8851806f, topicName=脑靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Dec 25 14:21:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538569, encodeId=c918153856967, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Aug 12 07:21:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-08-12 saikp

相关资讯

Circulation:复旦大学研究发现空气净化器能有效减少PM2.5对人体的伤害

由复旦大学的研究人员对年轻学生采取的一项研究显示:暴露于高浓度的空气污染会增加应激激素水平和负面的代谢变化。相关文章发表在美国心脏协会杂志Circulation上,该研究表明空气净化器似乎能减轻负面影响。

复旦大学建综合大学中西医结合临床基地

12月16日,复旦大学中西医结合研究院临床基地在上海市青浦区中医院挂牌,首开综合性大学开设中医及中西医结合临床基地之先河。同时,复旦大学附属华山医院与青浦区卫生计生委签订战略合作协议,共同推进复旦大学中西医结合研究院青浦临床基地建设。

EAU18∣叶定伟教授团队:DNA修复基因功能性突变与肾癌靶向治疗耐药相关

肾癌约占所有成人恶性肿瘤的3-4%,是我国泌尿系统肿瘤第三大癌种。其中有将近一半的患者以转移性疾病起病或进展至全身转移。靶向治疗一定程度改善了晚期肾癌预后,但并非所有人都能从中获益,部分患者对靶向治疗可发生耐药。提前预测患者对靶向治疗的敏感性有助于更精准地药物治疗选择。

《转》访复旦大学生命科学学院卢大儒教授:单倍型分析及其应用

《转》访是转化医学网的品牌专访栏目,是业内专家、大佬、知名企业智慧交流碰撞的平台,也是促进行业健康发展的重要力量,《转》访致力于打造转化医学领域最知名的专家访谈栏目。

复旦大学附属肿瘤医院创新患教形式 用漫画解抗乳癌难题

中国是乳腺癌发病大国,在所有乳腺癌患者中,约60-70%的患者雌激素受体表达阳性需接受内分泌治疗。如何向患者通俗易懂地解释乳腺癌内分泌患者在治疗和康复期间可能碰到的种种问题及其攻略?上海的医务工作者们别具心裁地用创意漫画的形式,让乳腺癌内分泌治疗患者在繁杂的信息环境,获得权威、有效、趣味的康复方法。8日,复旦大学附属肿瘤医院发布了首部《乳腺癌内分泌治疗患者手册》。粉嫩的颜色、Q萌的漫画人物,一下子

复旦大学上海医学院就女博士涉情感纠葛传闻发声明:医学院高度重视,已会同中山医院启动调查

今日(7月27日)凌晨,复旦大学上海医学院就近日网传的该院女博士生与附属中山医院青年研究员情感纠葛传闻发表声明。